Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Association Between Tumor Necrosis Factor-x and Disease Progression in Patients with Multiple Sclerosis
NEJM 325:467-472, Shareif,M.K.&Hentges,R., 1991